China Pharma Holdings Total Assets 2012-2026 | CPHI
China Pharma Holdings total assets from 2012 to 2026. Total assets can be defined as the sum of all assets on a company's balance sheet.
|
China Pharma Holdings Annual Total Assets (Millions of US $) |
|
|---|---|
| 2025 | $31 |
| 2024 | $15 |
| 2023 | $16 |
| 2022 | $18 |
| 2021 | $23 |
| 2020 | $21 |
| 2019 | $22 |
| 2018 | $45 |
| 2017 | $60 |
| 2016 | $79 |
| 2015 | $97 |
| 2014 | $121 |
| 2013 | $158 |
| 2012 | $163 |
| 2011 | $156 |
|
China Pharma Holdings Quarterly Total Assets (Millions of US $) |
|
|---|---|
| 2026-03-31 | $45 |
| 2025-12-31 | $31 |
| 2025-09-30 | $16 |
| 2025-06-30 | $14 |
| 2025-03-31 | $14 |
| 2024-12-31 | $15 |
| 2024-09-30 | $13 |
| 2024-06-30 | $14 |
| 2024-03-31 | $16 |
| 2023-12-31 | $16 |
| 2023-09-30 | $15 |
| 2023-06-30 | $16 |
| 2023-03-31 | $17 |
| 2022-12-31 | $18 |
| 2022-09-30 | $16 |
| 2022-06-30 | $18 |
| 2022-03-31 | $21 |
| 2021-12-31 | $23 |
| 2021-09-30 | $18 |
| 2021-06-30 | $20 |
| 2021-03-31 | $20 |
| 2020-12-31 | $21 |
| 2020-09-30 | $21 |
| 2020-06-30 | $23 |
| 2020-03-31 | $22 |
| 2019-12-31 | $22 |
| 2019-09-30 | $40 |
| 2019-06-30 | $43 |
| 2019-03-31 | $45 |
| 2018-12-31 | $45 |
| 2018-09-30 | $53 |
| 2018-06-30 | $58 |
| 2018-03-31 | $62 |
| 2017-12-31 | $60 |
| 2017-09-30 | $75 |
| 2017-06-30 | $77 |
| 2017-03-31 | $78 |
| 2016-12-31 | $79 |
| 2016-09-30 | $87 |
| 2016-06-30 | $92 |
| 2016-03-31 | $97 |
| 2015-12-31 | $97 |
| 2015-09-30 | $109 |
| 2015-06-30 | $121 |
| 2015-03-31 | $118 |
| 2014-12-31 | $121 |
| 2014-09-30 | $141 |
| 2014-06-30 | $146 |
| 2014-03-31 | $154 |
| 2013-12-31 | $158 |
| 2013-09-30 | $162 |
| 2013-06-30 | $159 |
| 2013-03-31 | $159 |
| 2012-12-31 | $163 |
| 2012-09-30 | $166 |
| 2012-06-30 | $165 |
| 2012-03-31 | $164 |
| 2011-12-31 | $156 |
| 2011-09-30 | $151 |
| 2011-06-30 | $143 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.026B | $0.004B |
| CHINA PHARMA HOLDINGS, Inc. develops, manufactures, and markets generic and brand bio-pharmaceutical products in China that treat a wide range of conditions, including infections, hepatitis, cardiovascular and CNS diseases, and other prevailing diseases. Helpson Bio-pharmaceutical Co., Ltd. (Helpson), a specialty pharmaceutical company headquartered in Haikou City, Hainan province in China, is a wholly owned subsidiary of China Pharma Holdings. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |